Feb. 18, 2014, 9:56 AM
- Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less common serious side-effects.
- Dynavax plans to soon start another Heplisav trial in order to provide a large enough database. (PR)
eMagin Corp is a manufacturer of microdisplays using OLED technology. It designs, develops, manufactures, and markets OLED on silicon microdisplays, virtual imaging products and related products.
Other News & PR